Bayer Will Continue To Develop Repinotan Despite Cutting Stroke Research

Bayer plans to continue Phase III development of stroke drug repinotan despite terminating research on other stroke candidates.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet